Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 7.68B |
| Revenue (ttm) | 334.12M |
| Net Income (ttm) | -203.68M |
| Shares Out | 67.10M |
| EPS (ttm) | -3.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $114.53 |
| Previous Close | $115.71 |
| Change ($) | -1.18 |
| Change (%) | -1.02% |
| Day's Open | 113.67 |
| Day's Range | 112.05 - 117.50 |
| Day's Volume | 664,271 |
| 52-Week Range | 61.96 - 179.65 |
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
Ultragenyx (RARE) delivered earnings and revenue surprises of -62.40% and 33.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
First quarter 2021 total revenue of $99.4 million and Crysvita 1 revenue to Ultragenyx of $42.1 million
NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri...
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel therapies for serious rare and ultra-rar...
NOVATO, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...
SAN DIEGO--(BUSINESS WIRE)-- #ASOs--n-Lorem Foundation Partners with Ultragenyx to Bolster Development of Personalized Medicines for Patients with Ultra-Rare Diseases
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
The FDA clears Ultragenyx's (RARE) investigational new drug application for UX053 being developed to treat Glycogen Storage Disease Type III.
NOVATO, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...
NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...
Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fat...
First Approved Treatment for Adult and Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) in Canada First Approved Treatment for Adult and Pediatric Patients with Long-chain Fat...
Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.
Ultragenyx (RARE) delivered earnings and revenue surprises of -26.42% and 28.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 77.16% over the past year to ($0.37), whic...
2020 total revenue of $271.0 million and 2020 Crysvita 1 revenue to Ultragenyx of $138.9 million
NOVATO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare ...
Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.
Clinical trial will utilize a single-protocol Phase 1/2/3 design
Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.
Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC
NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare ...
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
The recent acquisition of rare dug heavyweight Alexion Pharmaceuticals signals a willingness of big pharma to enter the field. Typically, big pharma was interested in larger patient populations however ...
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise
Ultragenyx (RARE) gets Orphan Drug Designation from the FDA for UX701 for the treatment of Wilson disease.
NOVATO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare a...
Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit
NOVATO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...
State-of-the-art facility to be located in Bedford, Massachusetts
NOVATO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seriou...
NOVATO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...
Stock Market Crumbles; Indexes Dive, More Leaders Break; Monolithic Power, Ultragenyx Strong
Stock market crumbles: Indexes Dive More Leaders Break; Monolithic Power, Ultragenyx strong. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, ...
NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...
Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.
NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious...
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call Transcript
Ultragenyx (RARE) delivered earnings and revenue surprises of 8.87% and 47.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx Pharmaceutical posted third-quarter results late Tuesday that beat views on the top and bottom lines after RARE stock hit a nearly five-year high, revenue more than triples. The post Ultragen...
Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 42.35% over the past year to ($1.13),...
Third quarter 2020 total revenue of $ 81.5 million and Crysvita 1 revenue of $37.3 million
Efficacy in multiple functional measures observed in all five patients treated
- Collaboration combines Solid's differentiated microdystrophin construct and Ultragenyx's HeL a PCL manufacturing platform for use with AAV8 and variants -
NOVATO, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio...
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolv... [Read more...]
| Industry Biotechnology | IPO Date Jan 31, 2014 |
| CEO Emil Kakkis | Employees 893 |
| Stock Exchange NASDAQ | Ticker Symbol RARE |
Financial Performance
In 2020, RARE's revenue was $271.03 million, an increase of 161.32% compared to the previous year's $103.71 million. Losses were -$186.57 million, -53.67% less than in 2019.
Analyst Forecasts
According to 15 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is 153.19, which is an increase of 33.76% from the latest price.